Summary.-In a longitudinal study of the evolution of serum p2-microglobulin (p2-m) levels in 37 patients with myelomatosis, those patients with a level of <4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of >4 mg/l had a median survival of 15 months. The p2-m appeared to be independent of the level of the paraprotein and its class, as seen in a vertical study of 129 patients. Analysis of the influence of a rising serum creatinine on the serum p2-im indicates that p2-rm production is excessive in advanced disease with or without renal failure. Practical application of the measurement of serum p2-m in the stratification and monitoring of patients is suggested.
SEVERAL INDICES have been proposed for the clinical stratification of multiple myelomatosis. The system devised by Durie & Salmon (1975) , using a panel of clinical biochemical factors, has the advantage of being correlated with survival and predictive of the response to treatment. Hence any new biochemical test, to be considered seriously for the stratification of multiple myelomatosis, must be capable of providing information comparable to the more complex systems in current use. There is growing evidence that serum P2-microglobulin (32-m) level is often increased in multiple myelomatosis (Shuster et al., 1976; Belleville et al., 1978) . However, P2-m is a low-mol. wt. protein (11,800 dalton) and its serum levels depend on both its production and its renal clearance. Elevation of serum /2-m occurs in renal clearance. Elevation of serum :2-m occurs in renal impairment (Revillard, 1979) . As some form of renal involvement will occur eventually in about half of the patients with multiple myelomatosis (DeFronzo et al., 1978) it could be argued that the measurement of serum /2-m is only providing refined information about multiple myeloma that might be of particular importance in patients with normal serum creatinine, and may be a simple substitute for the serial measurement of paraprotein levels in the monitoring of multiple myelomatosis.
PATIENTS AND METHODS
Two group of patients were studied; all fulfilled the accepted criteria for the diagnosis of myelomatosis (Chronic Leukaemia-Myeloma Task Force, 1973 Kaplan & Meier (1958) and the significance between the survival of the subsets calculated by the log-rank method (Peto et al., 1977 The serum /2-mn was measured by the Phadebas radioimmunoassay (Pharmacia, Uppsala, Sweden). The normal limits for this assay in blood donors are 0 8-2-4 mg/l. Creactive protein was measured by radial immunodiffusion, using antisera and standards obtained from the Behring Institut, Marburg/Lahn, Germany. Serum levels > 10 mg/l were considered abnormal, but a discriminant level of 20 mg/l was adopted as being indicative of active infection. Serum creatinine was measured by Jaffe's method: a value of 140 HM wNas arbitrarily taken as the upper limit of normal in this population. The choice of the serum /2-m 4 mg/l cut-off as the basis for stratification of the patients into good and bad prognosis groups wAas made after reference to results obtained in "normal" subjects, over 60 years of age, AN-here the median was 2-2 mg/l and range 1 2-40 mg/l (Agerup, personal communication) .
RESULTS
The general relationship between serum /2-m level at first presentation and the probability of survival in Group I, is shown in Fig. 1 The relation of serum f2-m levels and creatinine levels in patients in whom renal impairment is indicated by elevated creatinine, is shown in Fig. 4 , where comparison is made with the regression slopes for these variates in chronic renal failure and systemic lupus erythematosus, as published by Hall (1979) . It will be seen that there is a wide range of serum ,82-m levels for a particular creatinine level. The correlation coefficient, as measured by the Spearman ranking test, was r = 0-61, P = 0.01. In the longitudinal studies, levels of serum ,B2-m > 15 mg/l were always associated with creatinine > 140 ,uM. But considerable change in serum ,82-m levels, either downwards during the reduction of the larger tumour burdens or upwards as the mass expanded, could occur without a coincidental change in serum creatinine.
DISCUSSION
The discriminant power of serum ,B2-m level of 4 mg/l is apparent from the survival studies (Fig. 1) where good and bad prognostic groups are distinguished. It will require a larger series to define the level for optimal separation of these 2 groups. There is also a clear relation between serum /2-m levels and estimates Hall (1979) .
of tumour mass, using the system devised by Durie & Salmon ( Once the creatinine begins to rise, the effect of hyperproduction is magnified and the serum /2-m is elevated more than is usual for chronic renal disease. Assuming that the raised levels are due to excess production, it is not known whether this P2-m comes from the mature plasma cells, their precursors or other cells of the lymphoid series. Studies of lymphoid disease indicate that raised serum /32-m can accompany a variety of benign and malignant diseases involving B or T lymphocytes (Cooper & Spati, 1979) . Whatever the cell type or types contributing to the production df /2-m, its origin is most probably from the turnover of HLA on cell membranes, where /2-m forms the light chain of HLA (Cresswell et at., 1974) .
In practice the measurement of serum /32-m, at first presentation, would appear to be useful for the stratification of multiple myeloma, especially when the creatinine level is normal. The frequency of a renal impairment at first presentation has been reported as 43/237 (18-1%) by Woodruff et al. (1979) , and 18% by Alexanian et al. (1975) using criteria less strict than ours.
High levels of serum P2-m at diagnosis or after 12-18 months carry a poor prognosis, and such levels are frequently encountered in IgA and IgG myeloma without an elevated serum creatinine (Table II) . Furthermore, serum /2-m could well be a better reflection of the tumour mass than the serum paraprotein levels, and may offer a particular advantage for the monitoring of Bence Jones myelomatosis, as it is difficult to measure the serum concentrations of light chains accurately. Severe acute infections do not necessarily raise serum 32-m, which is independent of the serum acute-phase reactive protein response (Cooper & Spati, 1979) . This may account for the lack of rise of P2-m in the terminal periods of life of those patients in Fig. 1 and 2 whose intercurrent infection was the immediate cause of death.
Measurement of serum 32-m is simpler and less problematical than existing staging systems and paraprotein estimations. It may prove particularly applicable to the stratification and subsequent monitoring of patients with myelomatosis in the multi-centre clinical trial.
